Symbols / ALXO
ALXO Chart
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 320.12M |
| Enterprise Value | 86.19M | Income | -108.01M | Sales | — |
| Book/sh | 0.84 | Cash/sh | 1.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 44 | IPO | — |
| P/E | — | Forward P/E | -3.25 | PEG | — |
| P/S | — | P/B | 2.92 | P/C | — |
| EV/EBITDA | -0.80 | EV/Sales | — | Quick Ratio | 2.20 |
| Current Ratio | 2.40 | Debt/Eq | 34.84 | LT Debt/Eq | — |
| EPS (ttm) | -2.01 | EPS next Y | -0.75 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-27 | ROA | -50.50% |
| ROE | -118.95% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 131.20M |
| Shs Float | 42.85M | Short Float | 3.31% | Short Ratio | 3.36 |
| Short Interest | — | 52W High | 2.66 | 52W Low | 0.40 |
| Beta | 0.52 | Avg Volume | 448.47K | Volume | 281.72K |
| Target Price | $3.33 | Recom | None | Prev Close | $2.42 |
| Price | $2.44 | Change | 0.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.33
Mean price target
2. Current target
$2.45
Latest analyst target
3. DCF / Fair value
$-8.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.45
Low
$2.00
High
$4.00
Mean
$3.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-05 | main | Piper Sandler | Overweight → Overweight | $4 |
| 2025-05-21 | main | UBS | Buy → Buy | $1 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-03-07 | main | Stifel | Hold → Hold | $2 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-06 | main | Piper Sandler | Overweight → Overweight | $9 |
| 2025-03-06 | up | Jefferies | Hold → Buy | $3 |
| 2025-01-27 | main | UBS | Buy → Buy | $2 |
| 2025-01-24 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-01-24 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-19 | down | Jefferies | Buy → Hold | $2 |
| 2024-12-18 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-11-12 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-16 | main | UBS | Buy → Buy | $4 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-12 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-09 | reit | Stifel | Hold → Hold | $3 |
| 2024-08-01 | main | Stifel | Hold → Hold | $5 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
- Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 09 Feb 2026 08
- Breast cancer trial finds CD47 signal tied to drug response - Stock Titan Fri, 30 Jan 2026 08
- ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks - simplywall.st Mon, 12 Jan 2026 08
- $ALXO stock is up 34% today. Here's what we see in our data. - Quiver Quantitative Mon, 18 Aug 2025 07
- Alx Oncology stock soars after impressive lymphoma treatment results - Investing.com Mon, 08 Dec 2025 08
- ALX Oncology Highlights Biomarker Data and Cash Position - TipRanks Fri, 30 Jan 2026 08
- Alx Oncology Faces Nasdaq Delisting Risk Amid Stock Price Slump - The Globe and Mail Fri, 15 Aug 2025 07
- Friday 9/19 Insider Buying Report: AROC, ALXO - Nasdaq Fri, 19 Sep 2025 07
- Insider Buys Additional US$58k In ALX Oncology Holdings Stock - simplywall.st hu, 21 Aug 2025 07
- Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Raises Target Price to $4 - 富途牛牛 hu, 05 Feb 2026 08
- ALX Oncology Holdings Inc. to Report Second Quarter 2025 Financial Results and Business Update on August 12, 2025 | ALXO Stock News - Quiver Quantitative ue, 05 Aug 2025 07
- ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance Wed, 13 Aug 2025 07
- ALX Oncology Expands Inducement Equity Plan for Hiring - TipRanks Wed, 21 Jan 2026 08
- ALX Oncology announces pricing of underwritten offering; shares up nearly 15% - MSN Wed, 11 Feb 2026 01
- symbol__ Stock Quote Price and Forecast - CNN ue, 03 Oct 2023 15
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 565 | 1283 | — | Sale at price 2.27 per share. | PINTO SHELLY | Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 3184713 | 4999999 | — | Purchase at price 1.57 per share. | GOODMAN COREY S | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-02 00:00:00 | I |
| 2 | 3925 | 4357 | — | Sale at price 1.11 per share. | PINTO SHELLY | Officer | — | 2026-01-06 00:00:00 | D |
| 3 | 92233 | 99352 | — | Purchase at price 1.07 - 1.08 per share. | LETTMANN JASON | Chief Executive Officer | — | 2025-09-17 00:00:00 | D |
| 4 | 75000 | 58402 | — | Purchase at price 0.78 per share. | SHANTHARAM HARISH | Chief Financial Officer | — | 2025-08-18 00:00:00 | D |
| 5 | 2382 | 1525 | — | Sale at price 0.64 per share. | LETTMANN JASON | Chief Executive Officer | — | 2025-08-15 00:00:00 | D |
| 6 | 611 | 391 | — | Sale at price 0.64 per share. | PINTO SHELLY | Officer | — | 2025-08-15 00:00:00 | D |
| 7 | 2011 | 905 | — | Sale at price 0.45 per share. | PINTO SHELLY | Officer | — | 2025-07-07 00:00:00 | D |
| 8 | 1532 | 659 | — | Sale at price 0.43 per share. | PINTO SHELLY | Officer | — | 2025-06-30 00:00:00 | D |
| 9 | 42000 | — | — | Stock Award(Grant) at price 0.00 per share. | LETTMANN JASON | Chief Executive Officer | — | 2025-03-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -132.25M | -158.40M | -122.84M | -83.42M |
| TotalUnusualItems | 0.00 | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -134.85M | -160.81M | -123.48M | -83.46M |
| ReconciledDepreciation | 872.00K | 836.00K | 342.00K | 51.00K |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | -132.25M | -158.40M | -122.84M | -83.42M |
| EBIT | -133.12M | -159.24M | -123.18M | -83.47M |
| NetInterestIncome | 7.64M | 9.08M | 4.04M | 78.00K |
| InterestExpense | 1.73M | 1.56M | 238.00K | 13.00K |
| InterestIncome | 9.37M | 10.65M | 4.28M | 91.00K |
| NormalizedIncome | -134.85M | -160.81M | -123.48M | -83.46M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -134.85M | -160.81M | -123.48M | -83.46M |
| TotalExpenses | 142.47M | 170.28M | 127.44M | 83.56M |
| TotalOperatingIncomeAsReported | -142.47M | -170.28M | -127.44M | -83.56M |
| DilutedAverageShares | 52.17M | 42.99M | 40.70M | 40.31M |
| BasicAverageShares | 52.17M | 42.99M | 40.70M | 40.31M |
| DilutedEPS | -2.58 | -3.74 | -3.03 | -2.07 |
| BasicEPS | -2.58 | -3.74 | -3.03 | -2.07 |
| DilutedNIAvailtoComStockholders | -134.85M | -160.81M | -123.48M | -83.46M |
| NetIncomeCommonStockholders | -134.85M | -160.81M | -123.48M | -83.46M |
| NetIncome | -134.85M | -160.81M | -123.48M | -83.46M |
| NetIncomeIncludingNoncontrollingInterests | -134.85M | -160.81M | -123.48M | -83.46M |
| NetIncomeContinuousOperations | -134.85M | -160.81M | -123.48M | -83.46M |
| TaxProvision | 0.00 | 0.00 | 64.00K | -21.00K |
| PretaxIncome | -134.85M | -160.81M | -123.42M | -83.48M |
| OtherIncomeExpense | -20.00K | 389.00K | -22.00K | -7.00K |
| OtherNonOperatingIncomeExpenses | -20.00K | 389.00K | -22.00K | -7.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 7.64M | 9.08M | 4.04M | 78.00K |
| InterestExpenseNonOperating | 1.73M | 1.56M | 238.00K | 13.00K |
| InterestIncomeNonOperating | 9.37M | 10.65M | 4.28M | 91.00K |
| OperatingIncome | -142.47M | -170.28M | -127.44M | -83.56M |
| OperatingExpense | 142.47M | 170.28M | 127.44M | 83.56M |
| ResearchAndDevelopment | 116.37M | 141.79M | 98.40M | 60.17M |
| SellingGeneralAndAdministration | 26.09M | 28.48M | 29.04M | 23.39M |
| GeneralAndAdministrativeExpense | 26.09M | 28.48M | 29.04M | 23.39M |
| OtherGandA | 9.87M | 9.78M | 10.17M | 23.39M |
| SalariesAndWages | 16.22M | 18.71M | 18.86M | 14.05M |
| GrossProfit | 0.00 | 0.00 | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 53.05M | 49.95M | 40.86M | 40.59M |
| ShareIssued | 53.05M | 49.95M | 40.86M | 40.59M |
| TotalDebt | 9.90M | 9.64M | 9.39M | 742.00K |
| TangibleBookValue | 113.62M | 189.71M | 263.46M | 363.05M |
| InvestedCapital | 123.52M | 199.35M | 272.85M | 363.05M |
| WorkingCapital | 115.85M | 152.66M | 242.64M | 351.72M |
| NetTangibleAssets | 113.62M | 189.71M | 263.46M | 363.05M |
| CapitalLeaseObligations | 7.56M | 1.04M | 742.00K | |
| CommonStockEquity | 113.62M | 189.71M | 263.46M | 363.05M |
| TotalCapitalization | 123.09M | 199.35M | 272.85M | 363.05M |
| TotalEquityGrossMinorityInterest | 113.62M | 189.71M | 263.46M | 363.05M |
| StockholdersEquity | 113.62M | 189.71M | 263.46M | 363.05M |
| GainsLossesNotAffectingRetainedEarnings | 275.00K | 256.00K | -845.00K | 0.00 |
| OtherEquityAdjustments | 275.00K | 256.00K | -845.00K | |
| RetainedEarnings | -621.12M | -486.27M | -325.47M | -201.99M |
| AdditionalPaidInCapital | 734.41M | 675.68M | 589.74M | 564.99M |
| CapitalStock | 53.00K | 50.00K | 41.00K | 41.00K |
| CommonStock | 53.00K | 50.00K | 41.00K | 41.00K |
| TotalLiabilitiesNetMinorityInterest | 34.16M | 52.84M | 43.02M | 17.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.66M | 16.84M | 14.70M | 1.84M |
| OtherNonCurrentLiabilities | 6.19M | 7.20M | 5.31M | 1.84M |
| LongTermDebtAndCapitalLeaseObligation | 9.47M | 9.64M | 9.39M | |
| LongTermCapitalLeaseObligation | 5.98M | |||
| LongTermDebt | 9.47M | 9.64M | 9.39M | |
| CurrentLiabilities | 18.50M | 36.00M | 28.32M | 15.29M |
| OtherCurrentLiabilities | 2.57M | 2.21M | 2.05M | 236.00K |
| CurrentDebtAndCapitalLeaseObligation | 435.00K | 1.57M | 1.04M | 742.00K |
| CurrentCapitalLeaseObligation | 1.57M | 1.04M | 742.00K | |
| CurrentDebt | 435.00K | |||
| OtherCurrentBorrowings | 435.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.31M | 6.07M | 3.71M | 3.29M |
| PayablesAndAccruedExpenses | 10.19M | 27.73M | 22.57M | 11.02M |
| CurrentAccruedExpenses | 5.54M | 18.59M | 12.84M | 5.63M |
| Payables | 4.65M | 9.13M | 9.72M | 5.39M |
| OtherPayable | 1.63M | |||
| DuetoRelatedPartiesCurrent | 149.00K | 543.00K | 1.65M | 1.63M |
| TotalTaxPayable | 0.00 | |||
| IncomeTaxPayable | 0.00 | |||
| AccountsPayable | 4.50M | 8.59M | 8.07M | 3.76M |
| TotalAssets | 147.78M | 242.55M | 306.49M | 380.18M |
| TotalNonCurrentAssets | 13.42M | 53.89M | 35.52M | 13.16M |
| OtherNonCurrentAssets | 200.00K | 200.00K | 288.00K | |
| NonCurrentPrepaidAssets | 67.00K | 7.44M | 8.72M | 9.69M |
| NonCurrentAccountsReceivable | 78.00K | |||
| InvestmentsAndAdvances | 3.52M | 35.41M | 16.70M | 0.00 |
| InvestmentinFinancialAssets | 3.52M | 35.41M | 16.70M | 0.00 |
| AvailableForSaleSecurities | 3.52M | 35.41M | 16.70M | |
| NetPPE | 9.63M | 10.84M | 9.81M | 3.47M |
| AccumulatedDepreciation | -2.08M | -1.24M | -403.00K | -63.00K |
| GrossPPE | 11.71M | 12.08M | 10.22M | 3.54M |
| Leases | 2.51M | 2.51M | 2.36M | 229.00K |
| OtherProperties | 8.56M | 8.98M | 7.35M | 2.90M |
| MachineryFurnitureEquipment | 638.00K | 580.00K | 510.00K | 407.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 134.35M | 188.66M | 270.97M | 367.02M |
| OtherCurrentAssets | 6.59M | 5.92M | 4.76M | 3.35M |
| PrepaidAssets | 3.35M | |||
| CashCashEquivalentsAndShortTermInvestments | 127.76M | 182.74M | 266.21M | 363.67M |
| OtherShortTermInvestments | 110.19M | 160.33M | 217.38M | 0.00 |
| CashAndCashEquivalents | 17.57M | 22.41M | 48.82M | 363.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -122.36M | -131.64M | -90.65M | -73.02M |
| RepaymentOfDebt | -827.00K | -388.00K | -388.00K | -281.00K |
| IssuanceOfDebt | 0.00 | 0.00 | 10.00M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 58.89M | 0.00 | 0.00 |
| CapitalExpenditure | -447.00K | -1.27M | -1.43M | -4.92M |
| InterestPaidSupplementalData | 1.39M | 1.18M | 103.00K | 11.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 274.00K | |
| EndCashPosition | 17.63M | 22.47M | 48.89M | 363.67M |
| BeginningCashPosition | 22.47M | 48.89M | 363.67M | 434.22M |
| ChangesInCash | -4.84M | -26.42M | -314.78M | -70.55M |
| FinancingCashFlow | 30.82M | 59.29M | 9.86M | 2.47M |
| CashFlowFromContinuingFinancingActivities | 30.82M | 59.29M | 9.86M | 2.47M |
| NetOtherFinancingCharges | 29.66M | -655.00K | ||
| ProceedsFromStockOptionExercised | 1.98M | 792.00K | 903.00K | 2.75M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 58.89M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 58.89M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -827.00K | -388.00K | 9.61M | -281.00K |
| NetLongTermDebtIssuance | -827.00K | -388.00K | 9.61M | -281.00K |
| LongTermDebtPayments | -827.00K | -388.00K | -388.00K | -281.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | 10.00M | 0.00 |
| InvestingCashFlow | 86.26M | 44.66M | -235.42M | -4.92M |
| CashFlowFromContinuingInvestingActivities | 86.26M | 44.66M | -235.42M | -4.92M |
| NetInvestmentPurchaseAndSale | 86.70M | 45.93M | -233.99M | 0.00 |
| SaleOfInvestment | 194.11M | 292.56M | 142.80M | 0.00 |
| PurchaseOfInvestment | -107.41M | -246.63M | -376.79M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -4.26M | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -4.26M | |
| NetPPEPurchaseAndSale | -447.00K | -1.27M | -1.43M | -666.00K |
| PurchaseOfPPE | -447.00K | -1.27M | -1.43M | -666.00K |
| OperatingCashFlow | -121.91M | -130.36M | -89.22M | -68.10M |
| CashFlowFromContinuingOperatingActivities | -121.91M | -130.36M | -89.22M | -68.10M |
| ChangeInWorkingCapital | -12.43M | 8.30M | 9.85M | -4.03M |
| ChangeInOtherCurrentLiabilities | -2.07M | -2.35M | -977.00K | -698.00K |
| ChangeInOtherCurrentAssets | 7.38M | 1.37M | 750.00K | -9.68M |
| ChangeInPayablesAndAccruedExpense | -17.04M | 10.57M | 11.55M | 8.02M |
| ChangeInAccruedExpense | -12.62M | 11.22M | 7.03M | 3.31M |
| ChangeInPayable | -4.42M | -649.00K | 4.53M | 4.71M |
| ChangeInAccountPayable | -4.42M | -649.00K | 4.53M | 4.71M |
| ChangeInPrepaidAssets | -692.00K | -1.29M | -1.48M | -1.66M |
| ChangeInReceivables | 0.00 | 0.00 | ||
| OtherNonCashItems | 2.05M | 1.52M | 1.17M | 5.42M |
| StockBasedCompensation | 27.09M | 26.27M | 23.84M | 13.91M |
| AmortizationOfSecurities | -4.66M | -6.49M | -940.00K | 0.00 |
| DepreciationAmortizationDepletion | 872.00K | 836.00K | 342.00K | 51.00K |
| DepreciationAndAmortization | 872.00K | 836.00K | 342.00K | 51.00K |
| OperatingGainsLosses | 10.00K | |||
| GainLossOnSaleOfPPE | 10.00K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -134.85M | -160.81M | -123.48M | -83.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALXO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|